WallStreetZenWallStreetZen

NASDAQ: AKAN
Akanda Corp Stock

Overview
EarningsRevenueDividendOwnership
$1.56+0.01 (+0.65%)
Updated Dec 12, 2024
AKAN Price
$1.56
Fair Value Price
N/A
Market Cap
$2.02M
52 Week Low
$1.22
52 Week High
$56.80
P/E
0x
P/B
0.44x
P/S
1.76x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.24M
Earnings
-$29.08M
Gross Margin
-52.4%
Operating Margin
-2,336.84%
Profit Margin
-2,345.9%
Debt to Equity
1.18
Operating Cash Flow
-$3M
Beta
1.35
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

AKAN Overview

Akanda Corp. cultivates, manufactures, and distributes cannabis products in the U.K. and internationally. It suppies cannabis and cannabis-based medical and wellness products. The Company's subsidiaries include Bophelo Bio Science and Wellness (Pty) Limited, Canmart Limited, Bophelo Holdings Limited, Cannahealth Limited and Holigen Limited. Akanda was incorporated in 2021 and is headquartered in New Romney, U.K.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine AKAN's potential to beat the market

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
AKAN
RankedUnranked of 64

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Supernus Pharmaceuticals (SUPN)
$36.16A
Phibro Animal Health (PAHC)
$23.88A
Organogenesis Holdings (ORGO)
$3.53A
View Top Pharmaceutical Stocks

Be the first to know about important AKAN news, forecast changes, insider trades & much more!

AKAN News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AKAN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AKAN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AKAN is good value based on its book value relative to its share price (0.44x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.28x)
P/B vs Industry Valuation
AKAN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AKAN due diligence checks available for Premium users.

Valuation

AKAN price to earnings (PE)

For valuing profitable companies with steady earnings

Company
0x
Industry
9.22x
Market
29.87x

AKAN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.44x
Industry
2.28x
AKAN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AKAN's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
AKAN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AKAN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$10.0M
Liabilities
$5.4M
Debt to equity
1.18
AKAN's short-term assets ($7.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKAN's short-term assets ($7.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKAN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
AKAN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AKAN vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
AKAN–$2.02M+0.65%-0.00x0.44x
CTORC$2.52M-0.93%4.28x-0.83x
SHPHF$2.57M-5.53%-0.17x-1.95x
YCBD–$1.47M-2.74%-0.03x0.48x
QNTMD$3.07M-1.17%-0.38x0.26x
View Top Pharmaceutical Stocks

Akanda Stock FAQ

What is Akanda's quote symbol?

(NASDAQ: AKAN) Akanda trades on the NASDAQ under the ticker symbol AKAN. Akanda stock quotes can also be displayed as NASDAQ: AKAN.

If you're new to stock investing, here's how to buy Akanda stock.

What is the 52 week high and low for Akanda (NASDAQ: AKAN)?

(NASDAQ: AKAN) Akanda's 52-week high was $56.80, and its 52-week low was $1.22. It is currently -97.25% from its 52-week high and 27.87% from its 52-week low.

How much is Akanda stock worth today?

(NASDAQ: AKAN) Akanda currently has 1,297,343 outstanding shares. With Akanda stock trading at $1.56 per share, the total value of Akanda stock (market capitalization) is $2.02M.

Akanda stock was originally listed at a price of $8,400.00 in Mar 15, 2022. If you had invested in Akanda stock at $8,400.00, your return over the last 2 years would have been -99.98%, for an annualized return of -98.64% (not including any dividends or dividend reinvestments).

How much is Akanda's stock price per share?

(NASDAQ: AKAN) Akanda stock price per share is $1.56 today (as of Dec 12, 2024).

What is Akanda's Market Cap?

(NASDAQ: AKAN) Akanda's market cap is $2.02M, as of Dec 14, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Akanda's market cap is calculated by multiplying AKAN's current stock price of $1.56 by AKAN's total outstanding shares of 1,297,343.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.